Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael A Barry

Showing results (31-40 of 180) with videos related to

Pageof 18
Sort By:
Virology|September 22, 2009
Characterization of human adenovirus serotypes 5, 6, 11, and 35 as anticancer agentsElena V Shashkova, Shannon M May, Michael A Barry
Global Vaccines and Immunology|February 12, 2019
Comparison of systemic and mucosal immunization with replicating Single cycle AdenovirusesWilliam E Matchett, Stephanie S Anguiano-Zarate, Michael A Barry
Molecular Therapy : the Journal of the American Society of Gene Therapy|October 26, 2005
Activation of refractory T cell responses against hepatitis C virus core protein by ablation of interfering hydrophobic domainsHelen A Andersson, Rana A K Singh, Michael A Barry
Nature Reviews. Microbiology|June 17, 2008
Reprogrammed viruses as cancer therapeutics: targeted, armed and shieldedRoberto Cattaneo, Tanner Miest, Elena V Shashkova, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|December 9, 2004
Evaluation of polyethylene glycol modification of first-generation and helper-dependent adenoviral vectors to reduce innate immune responsesHoyin Mok, Donna J Palmer, Philip Ng, et al.
Journal of Immunology (Baltimore, Md. : 1950)|December 10, 2002
The role of T cell antagonism and original antigenic sin in genetic immunizationRana A K Singh, John R Rodgers, Michael A Barry
Journal of Virology|October 2, 2015
Comparison of the Life Cycles of Genetically Distant Species C and Species D Human Adenoviruses Ad6 and Ad26 in Human CellsMallory A Turner, Sumit Middha, Sean E Hofherr, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|September 17, 2009
Expanded anticancer therapeutic window of hexon-modified oncolytic adenovirusElena V Shashkova, Shannon M May, Konstantin Doronin, et al.
Current Gene Therapy|April 2, 2011
Advances and future challenges in adenoviral vector pharmacology and targetingReeti Khare, Christopher Y Chen, Eric A Weaver, et al.
Cancer Research|July 18, 2008
Macrophage depletion combined with anticoagulant therapy increases therapeutic window of systemic treatment with oncolytic adenovirusElena V Shashkova, Konstantin Doronin, Julien S Senac, et al.
Pageof 18

Showing results (31-40 of 180) with videos related to

Sort By:
Pageof 18
Virology|September 22, 2009
Characterization of human adenovirus serotypes 5, 6, 11, and 35 as anticancer agentsElena V Shashkova, Shannon M May, Michael A Barry
Global Vaccines and Immunology|February 12, 2019
Comparison of systemic and mucosal immunization with replicating Single cycle AdenovirusesWilliam E Matchett, Stephanie S Anguiano-Zarate, Michael A Barry
Molecular Therapy : the Journal of the American Society of Gene Therapy|October 26, 2005
Activation of refractory T cell responses against hepatitis C virus core protein by ablation of interfering hydrophobic domainsHelen A Andersson, Rana A K Singh, Michael A Barry
Nature Reviews. Microbiology|June 17, 2008
Reprogrammed viruses as cancer therapeutics: targeted, armed and shieldedRoberto Cattaneo, Tanner Miest, Elena V Shashkova, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|December 9, 2004
Evaluation of polyethylene glycol modification of first-generation and helper-dependent adenoviral vectors to reduce innate immune responsesHoyin Mok, Donna J Palmer, Philip Ng, et al.
Journal of Immunology (Baltimore, Md. : 1950)|December 10, 2002
The role of T cell antagonism and original antigenic sin in genetic immunizationRana A K Singh, John R Rodgers, Michael A Barry
Journal of Virology|October 2, 2015
Comparison of the Life Cycles of Genetically Distant Species C and Species D Human Adenoviruses Ad6 and Ad26 in Human CellsMallory A Turner, Sumit Middha, Sean E Hofherr, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|September 17, 2009
Expanded anticancer therapeutic window of hexon-modified oncolytic adenovirusElena V Shashkova, Shannon M May, Konstantin Doronin, et al.
Current Gene Therapy|April 2, 2011
Advances and future challenges in adenoviral vector pharmacology and targetingReeti Khare, Christopher Y Chen, Eric A Weaver, et al.
Cancer Research|July 18, 2008
Macrophage depletion combined with anticoagulant therapy increases therapeutic window of systemic treatment with oncolytic adenovirusElena V Shashkova, Konstantin Doronin, Julien S Senac, et al.
Pageof 18